SK282765B6 - 3-[4-(2-Fenyl-indol-1-ylmetyl)-fenyl]akrylamidy a 2-fenyl-1-[4- (amino-1-yl-alk-1-inyl)-benzyl]-1H-indol-5-oly, farmaceutický prostriedok s ich obsahom a ich použitie - Google Patents

3-[4-(2-Fenyl-indol-1-ylmetyl)-fenyl]akrylamidy a 2-fenyl-1-[4- (amino-1-yl-alk-1-inyl)-benzyl]-1H-indol-5-oly, farmaceutický prostriedok s ich obsahom a ich použitie Download PDF

Info

Publication number
SK282765B6
SK282765B6 SK471-97A SK47197A SK282765B6 SK 282765 B6 SK282765 B6 SK 282765B6 SK 47197 A SK47197 A SK 47197A SK 282765 B6 SK282765 B6 SK 282765B6
Authority
SK
Slovakia
Prior art keywords
phenyl
alkyl
methyl
compound
hydroxy
Prior art date
Application number
SK471-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK47197A3 (en
Inventor
Chris Paul Miller
Michael David Collini
Bach Dinh Tran
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of SK47197A3 publication Critical patent/SK47197A3/sk
Publication of SK282765B6 publication Critical patent/SK282765B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SK471-97A 1996-04-19 1997-04-15 3-[4-(2-Fenyl-indol-1-ylmetyl)-fenyl]akrylamidy a 2-fenyl-1-[4- (amino-1-yl-alk-1-inyl)-benzyl]-1H-indol-5-oly, farmaceutický prostriedok s ich obsahom a ich použitie SK282765B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63397296A 1996-04-19 1996-04-19
US63397696A 1996-04-19 1996-04-19

Publications (2)

Publication Number Publication Date
SK47197A3 SK47197A3 (en) 1997-11-05
SK282765B6 true SK282765B6 (sk) 2002-12-03

Family

ID=27092024

Family Applications (1)

Application Number Title Priority Date Filing Date
SK471-97A SK282765B6 (sk) 1996-04-19 1997-04-15 3-[4-(2-Fenyl-indol-1-ylmetyl)-fenyl]akrylamidy a 2-fenyl-1-[4- (amino-1-yl-alk-1-inyl)-benzyl]-1H-indol-5-oly, farmaceutický prostriedok s ich obsahom a ich použitie

Country Status (24)

Country Link
EP (1) EP0802184B1 (es)
JP (1) JPH1036347A (es)
KR (1) KR970069986A (es)
CN (1) CN1103756C (es)
AR (1) AR006705A1 (es)
AT (1) ATE219485T1 (es)
AU (1) AU718888B2 (es)
BR (1) BR9701879A (es)
CO (1) CO4950540A1 (es)
CZ (1) CZ293065B6 (es)
DE (1) DE69713441T2 (es)
DK (1) DK0802184T3 (es)
EA (1) EA000815B1 (es)
ES (1) ES2179273T3 (es)
HK (1) HK1002862A1 (es)
HU (1) HUP9700779A1 (es)
ID (1) ID16618A (es)
IL (1) IL120699A0 (es)
NO (1) NO308214B1 (es)
NZ (1) NZ314595A (es)
PT (1) PT802184E (es)
SK (1) SK282765B6 (es)
TW (1) TW397821B (es)
UA (1) UA47413C2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE339415T1 (de) * 1998-05-12 2006-10-15 Wyeth Corp Benzocarbazol und indenoindole derivate als östrogene agentien
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
CZ299334B6 (cs) * 1998-05-15 2008-06-25 Wyeth Farmaceutický prostredek
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
EP1080073A1 (en) * 1998-05-15 2001-03-07 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU2004200099B2 (en) * 1998-06-11 2006-11-02 Endorecherche, Inc. Medical Uses of A Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors
DK1212335T3 (da) * 1999-09-13 2006-03-20 Wyeth Corp Glucopyranosid-konjugater af 2-(4-hydroxyphenyl)-1-[4-(2-amin-1-ylethoxy)-benzyl]-1H-indol-5-oler
US6376486B1 (en) 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
CA2414111A1 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
EP1990051A1 (en) 2000-07-06 2008-11-12 Wyeth Combinations of SSRI and estrogenic agents
US6358991B2 (en) 2000-07-06 2002-03-19 American Home Products Corporation Methods of treating neuropeptide Y-related conditions
AU2001271782A1 (en) * 2000-07-06 2002-01-21 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
US6455568B2 (en) 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
AU2001271781A1 (en) * 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating sphincter incontinence
WO2002003986A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating breast disorders
AR029539A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Combinaciones de estatinas y agentes estrogenicos
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
US6369051B1 (en) 2000-07-06 2002-04-09 American Home Products Corporation Combinations of SSRI and estrogenic agents
AU2001271784A1 (en) * 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
EP1656938A1 (en) 2000-07-06 2006-05-17 Wyeth Combinations of SSRI and estrogenic agents
PT1401801E (pt) * 2000-08-24 2007-02-28 Univ Tennessee Res Foundation Modulares selectivos de receptor de androgénio e métodos para a sua utilização
CA2444787A1 (en) 2001-05-22 2002-11-28 Eli Lilly And Company Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
DE60210283T2 (de) 2001-05-22 2006-11-09 Eli Lilly And Co., Indianapolis 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
KR20060135866A (ko) 2004-04-07 2006-12-29 와이어쓰 바제독시펜 아세테이트의 결정질 다형체
PE20060173A1 (es) 2004-04-07 2006-04-12 Wyeth Corp Polimorfo cristalino de acetato de bazedoxifeno
MXPA06011686A (es) 2004-04-08 2006-12-14 Wyeth Corp Ascorbato de bazedoxifeno como modulador del receptor de estrogeno selectivo.
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7645881B2 (en) 2004-07-22 2010-01-12 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006042409A1 (en) 2004-10-20 2006-04-27 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
CN101277949A (zh) 2005-04-22 2008-10-01 阿兰托斯制药控股公司 二肽基肽酶-ⅳ抑制剂
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
CA2802761C (en) 2010-06-16 2017-01-03 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
KR102664618B1 (ko) * 2015-05-29 2024-05-10 에자이 알앤드디 매니지먼트 가부시키가이샤 사치환된 알켄 화합물 및 그의 용도
CN108366996B (zh) 2015-10-01 2021-04-09 奥列马制药公司 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物
EP3386500B1 (en) 2015-12-09 2022-09-07 The Board of Trustees of the University of Illinois Benzothiophene-based selective estrogen receptor downregulators
AU2017239348B2 (en) * 2016-03-25 2020-03-12 Luoxin Healthcare Science and Technology Development (Beijing) Ltd. Substituted-indole compounds as estrogen receptor down-regulators
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
AU2017290748A1 (en) 2016-07-01 2019-01-17 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
ES2954879T3 (es) 2016-11-28 2023-11-27 Eisai R&D Man Co Ltd Sales de derivado de indazol y cristales de las mismas
JP7229162B2 (ja) 2017-01-06 2023-02-27 ジー１ セラピューティクス， インコーポレイテッド 癌の治療に対する併用療法
CN110461853A (zh) 2017-02-10 2019-11-15 G1治疗公司 苯并噻吩雌激素受体调节剂
CN110913861B (zh) 2017-06-29 2024-01-09 G1治疗公司 G1t38的形态学形式及其制造方法
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3232968A1 (de) * 1981-09-10 1983-06-09 Degussa Ag, 6000 Frankfurt Neue 2-(hydroxy-phenyl)-indole und verfahren zu deren herstellung
DE3821148A1 (de) * 1988-06-23 1989-12-28 Erwin Von Dr Angerer Aminoalkylindole, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB9108811D0 (en) * 1991-04-24 1991-06-12 Erba Carlo Spa N-imidazolyl derivatives of substituted indole
RU2061694C1 (ru) * 1991-09-11 1996-06-10 Е.Р.Сквибб энд Санз, Инк., Производные индола
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
WO1993023374A1 (en) * 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Indole derivative
GB9326332D0 (en) * 1993-12-23 1994-02-23 Karo Bio Indole derivatives
ES2122555T3 (es) * 1994-02-22 1998-12-16 Merrell Pharma Inc Nuevos derivados indolicos utiles para tratar neoplasmas y trastornos relacionados con estrogenos.
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
ES2179273T3 (es) 2003-01-16
IL120699A0 (en) 1997-08-14
NO308214B1 (no) 2000-08-14
NZ314595A (en) 2000-04-28
HU9700779D0 (en) 1997-06-30
TW397821B (en) 2000-07-11
AR006705A1 (es) 1999-09-08
EP0802184A1 (en) 1997-10-22
EA000815B1 (ru) 2000-04-24
CZ117697A3 (en) 1997-12-17
SK47197A3 (en) 1997-11-05
HK1002862A1 (en) 1998-09-25
NO971814L (no) 1997-10-20
ATE219485T1 (de) 2002-07-15
AU718888B2 (en) 2000-04-20
PT802184E (pt) 2002-09-30
AU1892197A (en) 1997-10-23
JPH1036347A (ja) 1998-02-10
ID16618A (id) 1997-10-23
CZ293065B6 (cs) 2004-02-18
CO4950540A1 (es) 2000-09-01
CN1168373A (zh) 1997-12-24
BR9701879A (pt) 1998-09-29
DE69713441D1 (de) 2002-07-25
KR970069986A (ko) 1997-11-07
NO971814D0 (no) 1997-04-18
EA199700043A1 (ru) 1997-12-30
HUP9700779A1 (hu) 1999-09-28
UA47413C2 (uk) 2002-07-15
DK0802184T3 (da) 2002-09-16
CN1103756C (zh) 2003-03-26
EP0802184B1 (en) 2002-06-19
DE69713441T2 (de) 2002-11-07

Similar Documents

Publication Publication Date Title
EP0802184B1 (en) N-Benzyl-2-phenylindoles as estrogenic agents
US5880137A (en) 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5780497A (en) 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5985910A (en) 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents
US6924281B2 (en) 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
EP0802183B1 (en) Estrogenic agents
AU760378B2 (en) 2-phenyl-1-(4-(2-aminoethoxy)-benzyl)-indole in combination with estrogens
US20070142361A1 (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
EP1080073A1 (en) Compositions comprising 2-phenyl-indole compounds and estrogen formulations
US6583170B1 (en) 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
US6069153A (en) Indenoindoles and benzocarbazoles as estrogenic agents
CA2203079C (en) 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]indoles as estrogenic agents
MXPA97002866A (es) Agentes estrogenicos
CA2203073A1 (en) Estrogenic agents
CA2203074A1 (en) Estrogenic agents
MXPA00011170A (es) Composiciones que comprenden compuestos de 2-fenilindol y formulaciones de estrogeno